Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients

Stock Information for Rockwell Medical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rockwell Medical Inc.

Rockwell Medical Continues to Expand its Distribution Capabilities in Western United States
Rockwell Medical to Release First Quarter 2024 Results on Tuesday, May 14, 2024
Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda
Rockwell Medical Named 'Great Place to Work' for Second Year in a Row
Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023
Rockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund
Rockwell Medical Announces Third Quarter 2023 Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.